Phio Pharmaceuticals Corp. (PHIO)

Market Cap	14.17M +113.5%
Revenue (ttm)	n/a
Net Income	-8.70M
EPS	-1.45
Shares Out	11.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	257,646
Open	1.180
Previous Close	1.180
Day's Range	1.180 - 1.230
52-Week Range	0.813 - 4.190
Beta	0.91
Analysts	Strong Buy
Price Target	10.67 (+774.59%)
Earnings Date	Mar 5, 2026

About PHIO

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: PHIO
• Website: https://phiopharma.com

Analyst Summary

According to 3 analysts, the average rating for PHIO stock is "Strong Buy." The 12-month stock price target is $10.67, which is an increase of 774.59% from the latest price.

Price Target

$10.67

(774.59% upside)

Analyst Consensus: Strong Buy